{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:43:35Z","timestamp":1753875815075,"version":"3.41.2"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stratification of patients diagnosed with cancer has become a major goal in personalized oncology. One important aspect is the accurate prediction of the response to various drugs. It is expected that the molecular characteristics of the cancer cells contain enough information to retrieve specific signatures, allowing for accurate predictions based solely on these multi-omic data. Ideally, these predictions should be explainable to clinicians, in order to be integrated in the patients care. We propose a machine-learning framework based on ensemble learning to integrate multi-omic data and predict sensitivity to an array of commonly used and experimental compounds, including chemotoxic compounds and targeted kinase inhibitors. We trained a set of classifiers on the different parts of our dataset to produce omic-specific signatures, then trained a random forest classifier on these signatures to predict drug responsiveness. We used the Cancer Cell Line Encyclopedia dataset, comprising multi-omic and drug sensitivity measurements for hundreds of cell lines, to build the predictive models, and validated the results using nested cross-validation. Our results show good performance for several compounds (Area under the Receiver-Operating Curve &amp;gt;79%) across the most frequent cancer types. Furthermore, the simplicity of our approach allows to examine which omic layers have a greater importance in the models and identify new putative markers of drug responsiveness. We propose several models based on small subsets of transcriptional markers with the potential to become useful tools in personalized oncology, paving the way for clinicians to use the molecular characteristics of the tumors to predict sensitivity to therapeutic compounds.<\/jats:p>","DOI":"10.1093\/bib\/bbae567","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:40:26Z","timestamp":1730713226000},"source":"Crossref","is-referenced-by-count":0,"title":["Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity"],"prefix":"10.1093","volume":"25","author":[{"given":"S\u00e9bastien","family":"De Landtsheer","sequence":"first","affiliation":[{"name":"Department of Life Sciences and Medicine, University of Luxembourg , 2, place de l\u2019Universit\u00e9, L4365 Esch-sur-Alzette ,","place":["Luxembourg"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4120-1963","authenticated-orcid":false,"given":"Apurva","family":"Badkas","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Medicine, University of Luxembourg , 2, place de l\u2019Universit\u00e9, L4365 Esch-sur-Alzette ,","place":["Luxembourg"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Kulms","sequence":"additional","affiliation":[{"name":"Experimental Dermatology , Department of Dermatology, , 01307 Dresden ,","place":["Germany"]},{"name":"Technische Universit\u00e4t-Dresden , Department of Dermatology, , 01307 Dresden ,","place":["Germany"]},{"name":"National Center for Tumor Diseases, Technische Universit\u00e4t-Dresden , 01307 Dresden ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8225-2954","authenticated-orcid":false,"given":"Thomas","family":"Sauter","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Medicine, University of Luxembourg , 2, place de l\u2019Universit\u00e9, L4365 Esch-sur-Alzette ,","place":["Luxembourg"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"article-title":"Causes of death","year":"2022","author":"Ritchie","key":"2024110409401411700_ref1"},{"key":"2024110409401411700_ref2","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2024110409401411700_ref3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/pcmr.12459","article-title":"The genomic landscape of cutaneous melanoma","volume":"29","author":"Zhang","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"2024110409401411700_ref4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"key":"2024110409401411700_ref5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2024110409401411700_ref6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2020.11.045","article-title":"A modular master regulator landscape controls cancer transcriptional identity","volume":"184","author":"Paull","year":"2021","journal-title":"Cell"},{"key":"2024110409401411700_ref7","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1038\/s41388-021-01991-3","article-title":"Spontaneous and inherited TP53 genetic alterations","volume":"40","author":"Levine","year":"2021","journal-title":"Oncogene"},{"key":"2024110409401411700_ref8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.21037\/pcm-20-39","article-title":"A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications","volume":"3","author":"Sholl","year":"2020","journal-title":"Precis Cancer Med"},{"key":"2024110409401411700_ref9","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"The Lancet"},{"key":"2024110409401411700_ref10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"2024110409401411700_ref11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2024110409401411700_ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume-title":"Nature","author":"Barretina","year":"2012"},{"key":"2024110409401411700_ref13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41698-019-0078-1","article-title":"Artificial intelligence for precision oncology: beyond patient stratification","volume":"3","author":"Azuaje","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"2024110409401411700_ref14","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1016\/j.csbj.2021.07.003","article-title":"Machine learning in the prediction of cancer therapy","volume":"19","author":"Rafique","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"2024110409401411700_ref15","doi-asserted-by":"publisher","first-page":"bbab408","DOI":"10.1093\/bib\/bbab408","article-title":"An overview of machine learning methods for monotherapy drug response prediction","volume":"23","author":"Firoozbakht","year":"2022","journal-title":"Brief Bioinform"},{"key":"2024110409401411700_ref16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.275.5298.343","article-title":"An information-intensive approach to the molecular pharmacology of cancer","volume":"275","author":"Weinstein","year":"1997","journal-title":"Science"},{"key":"2024110409401411700_ref17","doi-asserted-by":"publisher","first-page":"10787","DOI":"10.1073\/pnas.191368598","article-title":"Chemosensitivity prediction by transcriptional profiling","volume":"98","author":"Staunton","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"2024110409401411700_ref18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"Veer","year":"2002","journal-title":"Nature"},{"key":"2024110409401411700_ref19","doi-asserted-by":"publisher","first-page":"i556","DOI":"10.1093\/bioinformatics\/btu464","article-title":"Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning","volume":"30","author":"G\u00f6nen","year":"2014","journal-title":"Bioinformatics"},{"key":"2024110409401411700_ref20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"2024110409401411700_ref21","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/gb-2014-15-3-r47","article-title":"Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines","volume":"15","author":"Geeleher","year":"2014","journal-title":"Genome Biol"},{"key":"2024110409401411700_ref22","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1093\/bioinformatics\/bty452","article-title":"Data and text mining predicting cancer drug response using a recommender system","volume":"34","author":"Suphavilai","year":"2018","journal-title":"Bioinformatics"},{"key":"2024110409401411700_ref23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12920-018-0460-9","article-title":"Predicting drug response of tumors from integrated genomic profiles by deep neural networks","volume":"12","author":"Chiu","year":"2019","journal-title":"BMC Med Genomics"},{"key":"2024110409401411700_ref24","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.celrep.2019.11.017","article-title":"A deep learning framework for predicting response to therapy in cancer","volume":"29","author":"Sakellaropoulos","year":"2019","journal-title":"Cell Rep"},{"key":"2024110409401411700_ref25","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.1038\/s41598-018-27214-6","article-title":"Cancer drug response profile scan (CDRscan): a deep learning model that predicts drug effectiveness from cancer genomic signature","volume":"8","author":"Chang","year":"2018","journal-title":"Sci Rep"},{"key":"2024110409401411700_ref26","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1038\/s41467-020-19313-8","article-title":"Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients","volume":"11","author":"Kong","year":"2020","journal-title":"Nat Commun"},{"key":"2024110409401411700_ref27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.18632\/oncotarget.28234","article-title":"CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling","volume":"13","author":"Pu","year":"2022","journal-title":"Oncotarget"},{"key":"2024110409401411700_ref28","doi-asserted-by":"publisher","first-page":"e61318","DOI":"10.1371\/journal.pone.0061318","article-title":"Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties","volume":"8","author":"Menden","year":"2013","journal-title":"PloS One"},{"key":"2024110409401411700_ref29","doi-asserted-by":"publisher","first-page":"e1004498","DOI":"10.1371\/journal.pcbi.1004498","article-title":"Predicting anticancer drug responses using a dual-layer integrated cell line-drug network model","volume":"11","author":"Zhang","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"2024110409401411700_ref30","doi-asserted-by":"publisher","first-page":"vbad110","DOI":"10.1093\/bioadv\/vbad110","article-title":"DPSP: a multimodal deep learning framework for polypharmacy side effects prediction","volume":"3","author":"Masumshah","year":"2023","journal-title":"Bioinforma Adv"},{"key":"2024110409401411700_ref31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12859-021-04298-y","article-title":"A neural network-based method for polypharmacy side effects prediction","volume":"22","author":"Masumshah","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"2024110409401411700_ref32","doi-asserted-by":"publisher","first-page":"bbae337","DOI":"10.1093\/bib\/bbae337","article-title":"MiRAGE: mining relationships for advanced generative evaluation in drug repositioning","volume":"25","author":"Hassanali Aragh","year":"2024","journal-title":"Brief Bioinform"},{"key":"2024110409401411700_ref33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13059-024-03293-9","article-title":"TMO-net: an explainable pretrained multi-omics model for multi-task learning in oncology","volume":"25","author":"Wang","year":"2024","journal-title":"Genome Biol"},{"key":"2024110409401411700_ref34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-023-00494-6","article-title":"Autosurv: interpretable deep learning framework for cancer survival analysis incorporating clinical and multi-omics data","volume":"8","author":"Jiang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2024110409401411700_ref35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/nbt.2877","article-title":"A community effort to assess and improve drug sensitivity prediction algorithms","volume":"32","author":"Costello","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2024110409401411700_ref36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0893-6080(05)80023-1","article-title":"Stacked generalization","volume":"5","author":"Wolpert","year":"1992","journal-title":"Neural Netw"},{"key":"2024110409401411700_ref37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12859-018-2060-2","article-title":"Investigation of model stacking for drug sensitivity prediction","volume":"19","author":"Matlock","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"2024110409401411700_ref38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"2024110409401411700_ref39","doi-asserted-by":"publisher","first-page":"W109","DOI":"10.1093\/nar\/gkq424","article-title":"Discovering causal signaling pathways through gene-expression patterns","volume":"38","author":"Parikh","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2024110409401411700_ref40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a Neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2024110409401411700_ref41","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024110409401411700_ref42","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1002\/cncr.32475","article-title":"Landscape of systemic therapy for ovarian cancer in 2019: primary therapy","volume":"125","author":"Fujiwara","year":"2019","journal-title":"Cancer"},{"key":"2024110409401411700_ref43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","article-title":"Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions","volume":"14","author":"Morabito","year":"2009","journal-title":"Oncologist"},{"key":"2024110409401411700_ref44","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2024110409401411700_ref45","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1021\/ml500526p","article-title":"Discovery of RAF265: a potent Mut-B-RAF inhibitor for the treatment of metastatic melanoma","volume":"6","author":"Williams","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"2024110409401411700_ref46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10549-008-0055-9","article-title":"Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer","volume":"115","author":"Dickler","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2024110409401411700_ref47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2007.11.009","article-title":"Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients","volume":"261","author":"Sai","year":"2008","journal-title":"Cancer Lett"},{"key":"2024110409401411700_ref48","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cancers12092718","article-title":"SFMBT2-mediated infiltration of preadipocytes and TAMs in prostate cancer","volume":"12","author":"Gwak","year":"2020","journal-title":"Cancer"},{"key":"2024110409401411700_ref49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/109759","article-title":"LEPREL1 expression in human hepatocellular carcinoma and its suppressor role on cell proliferation","volume":"2013","author":"Wang","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"2024110409401411700_ref50","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1080\/15548627.2020.1802091","article-title":"The roles of MAGEA6 variants in pancreatic cancer development and their potential impact on cancer immunotherapy","volume":"16","author":"Tsang","year":"2020","journal-title":"Autophagy"},{"key":"2024110409401411700_ref51","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41416-021-01476-w","article-title":"A wake-up call for cancer DNA damage: the role of schlafen 11 (SLFN11) across multiple cancers","volume":"125","author":"Zhang","year":"2021","journal-title":"Br J Cancer"},{"key":"2024110409401411700_ref52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","article-title":"Ror2 as a therapeutic target in cancer","volume":"150","author":"Debebe","year":"2015","journal-title":"Pharmacol Ther"},{"key":"2024110409401411700_ref53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/cancers13030383","article-title":"ROR2 is epigenetically regulated in endometrial cancer","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer"},{"key":"2024110409401411700_ref54","doi-asserted-by":"publisher","first-page":"e1431","DOI":"10.1002\/wrna.1431","article-title":"Emerging roles of hnRNPA1 in modulating malignant transformation","volume":"8","author":"Roy","year":"2017","journal-title":"WIREs RNA"},{"key":"2024110409401411700_ref55","doi-asserted-by":"publisher","first-page":"152736","DOI":"10.1016\/j.prp.2019.152736","article-title":"Overexpressed DAAM1 correlates with metastasis and predicts poor prognosis in breast cancer","volume":"216","author":"Mei","year":"2020","journal-title":"Pathol Res Pract"},{"key":"2024110409401411700_ref56","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","article-title":"Long noncoding RNA and cancer: a new paradigm","volume":"77","author":"Bhan","year":"2017","journal-title":"Cancer Res"},{"key":"2024110409401411700_ref57","doi-asserted-by":"publisher","first-page":"839540","DOI":"10.3389\/fgene.2022.839540","article-title":"SAWRPI: a stacking ensemble framework with adaptive weight for predicting ncRNA\u2013protein interactions using sequence information","volume":"13","author":"Ren","year":"2022","journal-title":"Front Genet"},{"key":"2024110409401411700_ref58","doi-asserted-by":"publisher","DOI":"10.1101\/2023.04.02.535254","article-title":"Modulation of SLFN11 induces changes in DNA damage response","volume":"23","author":"Raynaud","year":"2023","journal-title":"Cancer Cell Int"},{"key":"2024110409401411700_ref59","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"2024110409401411700_ref60","doi-asserted-by":"publisher","first-page":"604315","DOI":"10.3389\/fonc.2021.604315","article-title":"Identification of hub genes associated with sensitivity of 5-fluorouracil based chemotherapy for colorectal cancer by integrated bioinformatics analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2024110409401411700_ref61","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/0008-5472.CAN-19-1382","article-title":"ETV4 is necessary for estrogen signaling and growth in endometrial cancer cells","volume":"80","author":"Rodriguez","year":"2020","journal-title":"Cancer Res"},{"key":"2024110409401411700_ref62","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.bbrc.2019.06.115","article-title":"ETV4 promotes proliferation and invasion of lung adenocarcinoma by transcriptionally upregulating MSI2","volume":"516","author":"Cheng","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"2024110409401411700_ref63","doi-asserted-by":"publisher","first-page":"1121258","DOI":"10.3389\/fonc.2023.1121258","article-title":"Oncogenic role and drug sensitivity of ETV4 in human tumors: a pan-cancer analysis","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"2024110409401411700_ref64","doi-asserted-by":"publisher","first-page":"E5731","DOI":"10.1073\/pnas.1611532113","article-title":"SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling","volume":"113","author":"Koledova","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"2024110409401411700_ref65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-015-0318-0","article-title":"The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression","volume":"14","author":"Shi","year":"2015","journal-title":"Mol Cancer"},{"key":"2024110409401411700_ref66","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.biopha.2016.11.035","article-title":"Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma","volume":"85","author":"Zhou","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2024110409401411700_ref67","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12967-015-0595-9","article-title":"Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelial\u2013mesenchymal transition","volume":"13","author":"Xie","year":"2015","journal-title":"J Transl Med"},{"key":"2024110409401411700_ref68","doi-asserted-by":"publisher","first-page":"779483","DOI":"10.3389\/fonc.2021.779483","article-title":"A review on the role of SPRY4-IT1 in the carcinogenesis","volume":"11","author":"Ghafouri-Fard","year":"2022","journal-title":"Front Oncol"},{"key":"2024110409401411700_ref69","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.1158\/0008-5472.CAN-04-1669","article-title":"SPRY2 is an inhibitor of the Ras\/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant","volume":"64","author":"Tsavachidou","year":"2004","journal-title":"Cancer Res"},{"key":"2024110409401411700_ref70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/CBM-191226","article-title":"CMTM5\/7 are biomarkers and prognostic factors in human breast carcinoma","volume":"29","author":"Wu","year":"2020","journal-title":"Cancer Biomark"},{"key":"2024110409401411700_ref71","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2024110409401411700_ref72","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12885-015-1492-6","article-title":"Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection","volume":"15","author":"Dong","year":"2015","journal-title":"BMC Cancer"},{"key":"2024110409401411700_ref73","doi-asserted-by":"publisher","first-page":"9377","DOI":"10.1038\/s41598-020-65927-9","article-title":"Feature selection strategies for drug sensitivity prediction","volume":"10","author":"Koras","year":"2020","journal-title":"Sci Rep"},{"key":"2024110409401411700_ref74","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","article-title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers","volume":"11","author":"Horak","year":"2021","journal-title":"Cancer Discov"},{"key":"2024110409401411700_ref75","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"2024110409401411700_ref76","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024110409401411700_ref77","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol"},{"key":"2024110409401411700_ref78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1145\/3560442.3560445","volume-title":"2022 6th High Performance Computing and Cluster Technologies Conference (HPCCT)","author":"Varrette","year":"2022"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/6\/bbae567\/60387991\/bbae567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/25\/6\/bbae567\/60387991\/bbae567.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:40:29Z","timestamp":1730713229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbae567\/7874558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbae567","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"type":"print","value":"1467-5463"},{"type":"electronic","value":"1477-4054"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,9,23]]},"article-number":"bbae567"}}